Glenmark Launches COVID-19 Drug Favipiravir At Rs 103 Per Tablet

Glenmark Launches COVID-19 Drug Favipiravir At Rs 103 Per Tablet

Medical doctors say the Favipiravir’s actual efficacy can be recognized within the coming months

New Delhi:

As Glenmark Prescription drugs launched antiviral drug Favipiravir for the remedy of gentle to reasonable COVID-19 circumstances, medical consultants on Saturday cautioned towards seeing it as a “magic bullet” to deal with the lethal virus however stated it is going to be useful as it may be orally administered and cut back viral load.

They stated the drug’s actual efficacy can be recognized within the coming months.

Glenmark Prescription drugs stated it has launched antiviral drug Favipiravir, underneath the model identify FabiFlu, for the remedy of sufferers with gentle to reasonable COVID-19 at a value of about Rs 103 per pill.

FabiFlu is the primary oral Favipiravir-approved medicine in India for the remedy of COVID-19, it stated in an announcement.

“This drug was already being utilized in Japan for influenza. They’ve been utilizing it in COVID-19 sufferers additionally. Even China was utilizing it and Russia had additionally given permission in Might to make use of it. Antiviral medication like Remdesivir and Favipiravir will not be particular to COVID-19 however had been getting used for influenza,” stated Dr Vikas Maurya, Director, Division of Pulmonology and Sleep Problems, Fortis Hospital, Shalimar Bagh.

He stated research discovered that there was some advantage of Favipiravir in COVID-19 remedy and that’s the reason it has now been launched in India as nicely.

Dr Maurya stated with COVID-19 circumstances rising, the launching of the drug comes as a reduction.

“It’s not a magic bullet as it’s not the one factor we’ve got to offer. This isn’t a particular drug made for COVID-19 and has been discovered to be helpful, however how a lot it is going to be helpful we should see. Actual efficacy might be recognized when administered on a big scale,” he informed PTI.

“Neatest thing is that it’s an oral drug, whereas Ramdesiver is an intravenous drug. It (Favipiravir) may be even taken at house. So even whether it is giving some profit, it is going to be fairly helpful,” Dr Maurya stated.

Famous city-based lung surgeon Dr Arvind Kumar stated he doesn’t imagine that any of those antiviral medication like Remdisiver or Favipiravir might be recreation changers.

“If in any respect ”recreation changer” can be utilized, it’s for dexamethasone which has proven a major discount in mortality and is offered cheaply,” he stated.

There are such a lot of medicines out there and Favipiravir may also assist some sufferers, added Dr Kumar, who works at Sir Ganga Ram Hospital.

The Favipiravir drug might be out there as a 200 mg pill at a most retail value of Rs 3,500 for a strip of 34 tablets, Glenmark Prescription drugs stated.

It’s a prescription-based medicine with beneficial dose being 1,800 mg twice day by day on day one, adopted by 800 mg twice day by day as much as day 14, it added.

The tablets are being produced by the corporate at its Baddi facility in Himachal Pradesh. The drug might be out there each via hospitals and the retail channel, Glenmark stated.

The Mumbai-based agency had on Friday acquired the manufacturing and advertising and marketing approval from the Medication Controller Common of India (DCGI).

“This approval comes at a time when circumstances in India are spiralling like by no means earlier than, placing an amazing strain on our healthcare system,” Glenmark Prescription drugs Chairman and MD Glenn Saldanha stated within the assertion.

The corporate hopes that the provision of an efficient remedy similar to FabiFlu will significantly assist assuage this strain, and provide sufferers in India a a lot wanted possibility of well timed remedy, he added.

The approval’s restricted use entails accountable medicine utilization the place each affected person will need to have signed knowledgeable consent earlier than remedy initiation, Glenmark stated.

Favipiravir can be utilized for coronavirus sufferers with co-morbid situations similar to diabetes and coronary heart illness with gentle to reasonable COVID-19 signs, Glenmark added.

It gives fast discount in viral load inside 4 days and gives sooner symptomatic and radiological enchancment.

Favipiravir has proven medical enchancment of as much as 88 per cent in gentle to reasonable COVID-19 circumstances, it stated.

Contemplating the emergency and unmet medical want for COVID-19, the DCGI underneath the fast-tracked approval course of granted home agency Glenmark Prescription drugs the permission to fabricate and market Favipiravir (200 mg) pill.

Glenmark prescription drugs was the primary firm in India to provoke section three medical trials on Favipiravir for COVID-19 sufferers in India.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top